Compare Aurora Cannabis Inc (ACB) vs Core Scientific Inc (CORZ) Price & Performance

Aurora Cannabis (ACB) trades at $2.71, down 4.58% on the day, with a bearish technical outlook. The company reported a net income of $1.59 million in 2025, a significant improvement from a $69 million loss in 2024, though 2026 guidance projects a net loss of $136 million. Revenue grew to $343.29 million in 2025, but faces headwinds from Canadian reimbursement pressures. Analyst consensus is mixed, with 21.43% buy, 57.14% hold, and 21.43% sell ratings.

The stock's low P/B of 0.47 suggests undervaluation, but negative profitability metrics and a projected reset year in 2027 pose risks. Investment appeal hinges on execution in high-margin international medical markets, though volatility and competitive pressures remain key concerns for shareholders.

CORZ trades at $22.80, up 6.39% today, while showing bearish technical signals with a net cash outflow of $525.6M in 2025. The company is pivoting from Bitcoin mining to AI colocation, with Q1 2026 colocation revenue surging to $77.5M and gross margins of 57%. Despite missing earnings estimates for three consecutive quarters, analyst consensus remains strongly bullish with 86% buy ratings and a $33.43 price target.

The stock presents a high-risk, high-reward opportunity as the AI infrastructure transition accelerates. Near-term execution risks and negative profitability metrics contrast with substantial growth potential in the AI data center market. Wall Street optimism appears to outweigh current financial challenges, but investors should monitor cash flow improvements and contract execution.